ArticleJournal of biomedical research2024
Post-transcriptional dysregulation in autism, schizophrenia, and bipolar disorder.
Article in Journal of biomedical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mapping the Cerebral Organoid Landscape: A Systematic Review of Preclinical 3D Models in Neuroscience.Advanced healthcare materials · 2026Pooled it
- Epigenetic markers of response to psychotherapy in obsessive-compulsive disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Spatially resolved translational dysregulation inbioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The alteration of gene expression is not restricted to transcriptional regulation but includes a variety of post-transcriptional mechanisms; however, the role of the latter in many diseases remains relatively unknown. By using an RNA-Seq dataset of 1510 brain samples from individuals with autism spectrum disorder (ASD), bipolar disorder (BD), schizophrenia (SCZ), and controls, we assessed the contribution of post-transcriptional dysregulation and identified top perturbators accountable for transcriptomic alterations in neuropsychiatric disorders. Approximately 30% of the expression variability was attributed to post-transcriptional dysregulation. Interestingly, mature mRNA levels tended to be post-transcriptionally downregulated in SCZ and BD, leading to the inhibition of neurogenesis and neural differentiation, while they were upregulated in ASD, resulting in enhanced activity of apoptosis. These findings imply contrasting pathologies involving RNA metabolism across neuropsychiatric disorders. An RNA-binding protein, ELAVL3, was predicted to be significantly involved in the disruption of post-transcriptional regulation in all three disorders. To validate this, we knocked down its expression in cerebral organoids. Not only did the differentially expressed genes in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.